Russell Investments Group Ltd. Buys 5,728 Shares of Insulet Co. (NASDAQ:PODD)

Russell Investments Group Ltd. raised its stake in shares of Insulet Co. (NASDAQ:PODD) by 8.3% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 74,902 shares of the medical instruments supplier’s stock after acquiring an additional 5,728 shares during the quarter. Russell Investments Group Ltd.’s holdings in Insulet were worth $21,613,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of PODD. First Manhattan Co. bought a new position in shares of Insulet in the fourth quarter worth about $35,000. Quintet Private Bank Europe S.A. bought a new position in shares of Insulet in the first quarter worth about $36,000. Global Retirement Partners LLC increased its stake in shares of Insulet by 51.1% in the first quarter. Global Retirement Partners LLC now owns 133 shares of the medical instruments supplier’s stock worth $43,000 after purchasing an additional 45 shares during the period. Clear Street Markets LLC bought a new position in shares of Insulet in the first quarter worth about $43,000. Finally, Clearstead Advisors LLC increased its stake in shares of Insulet by 559.1% in the first quarter. Clearstead Advisors LLC now owns 145 shares of the medical instruments supplier’s stock worth $46,000 after purchasing an additional 123 shares during the period.

Analysts Set New Price Targets

PODD has been the topic of a number of recent analyst reports. Jefferies Financial Group upgraded Insulet from a “hold” rating to a “buy” rating and dropped their price objective for the stock from $260.00 to $240.00 in a research note on Monday, October 2nd. Robert W. Baird lowered Insulet from an “outperform” rating to a “neutral” rating and lowered their price target for the company from $320.00 to $219.00 in a research note on Monday, August 21st. Piper Sandler lowered their price target on Insulet from $325.00 to $250.00 and set an “overweight” rating on the stock in a research note on Friday, November 3rd. Leerink Partnrs restated an “outperform” rating on shares of Insulet in a research note on Monday, October 16th. Finally, JPMorgan Chase & Co. decreased their price objective on Insulet from $325.00 to $162.00 and set an “overweight” rating on the stock in a report on Tuesday, October 17th. Seven equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $254.80.

Insiders Place Their Bets

In other Insulet news, Director Shacey Petrovic sold 20,000 shares of the company’s stock in a transaction on Monday, November 13th. The stock was sold at an average price of $164.33, for a total transaction of $3,286,600.00. Following the transaction, the director now owns 2,567 shares of the company’s stock, valued at approximately $421,835.11. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, CEO James Hollingshead acquired 5,550 shares of Insulet stock in a transaction on Monday, August 28th. The shares were purchased at an average price of $181.41 per share, with a total value of $1,006,825.50. Following the acquisition, the chief executive officer now owns 34,177 shares in the company, valued at $6,200,049.57. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Shacey Petrovic sold 20,000 shares of the company’s stock in a transaction on Monday, November 13th. The stock was sold at an average price of $164.33, for a total value of $3,286,600.00. Following the transaction, the director now directly owns 2,567 shares in the company, valued at approximately $421,835.11. The disclosure for this sale can be found here. Company insiders own 0.90% of the company’s stock.

Insulet Stock Up 4.1 %

Shares of PODD opened at $181.26 on Tuesday. The company has a market capitalization of $12.66 billion, a P/E ratio of 106.00, a PEG ratio of 2.34 and a beta of 0.83. The company has a debt-to-equity ratio of 2.26, a current ratio of 3.26 and a quick ratio of 2.35. Insulet Co. has a one year low of $125.82 and a one year high of $335.91. The business’s 50 day simple moving average is $154.02 and its 200-day simple moving average is $225.54.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager.